NYSE$USPH

US Physical Therapy Inc · Q4 2019 earnings

Q4 2019 earnings · · Investor relations

Briefing

US Physical Therapy reported an increase in net revenues and operating income, but experienced higher employee healthcare costs than anticipated.

U.S. Physical Therapy reported a 4.1% increase in net revenues for Q4 2019, reaching $122.1 million, driven by growth in net patient revenues and the industrial injury prevention business. Operating income also rose by 3.3% to $15.3 million. However, the company faced challenges with higher employee healthcare costs, impacting overall profitability.

  • Net revenues increased by 4.1% to $122.1 million due to growth in physical therapy and industrial injury prevention.
  • Net patient revenues from physical therapy operations increased by 1.1% to $108.9 million.
  • Revenue from the industrial injury prevention business increased by 46.3% to $10.3 million.
  • Operating income increased by 3.3% to $15.3 million.

Headline financials

Total Revenue

$122M

Previous: $117M+4.1%
EPS (adj)

$0.64

Previous: $0.71-9.9%
Total Patient Visits

1.0M

Previous: 1.0M+1.3%
Net Income

$12M

No prior period
Operating Income

$15.3M

No prior period
Gross Profit

$27M

No prior period
Cash & Equivalents

$23.5M

No prior period
Total Assets

$561M

No prior period
Stock-Based Comp

$1.72M

No prior period

Revenue & EPS history

US Physical Therapy · Revenue · Quarterly

$122M

Q4 2019+4.1%vs Q4 2018
Beat estimate in 11 of 16 quarters(69%)
ActualEstimate

Revenue by segment

US Physical Therapy · $119M total across 2 segments · Q4 2019

  • Physical Therapy Operations
    $109M+1.1%
  • Injury Prevention
    $10.3M+47.1%

Forward guidance

Management expects the Company’s Operating Results for 2020 to be in the range of $38.1 million to $39.8 million or $2.98 to $3.10 per share.

Tailwinds

  • Expected Operating Results from existing operations
  • Includes the acquisition announced today
  • Based on an assumed annual corporate tax rate of approximately 26.5%
  • Company made a number of changes to it prescription drug program.
  • Various employee healthcare insurance programs renew annually on May 1.

Headwinds

  • Excludes future acquisitions
  • Excludes expenses associated with the scheduled retirement and replacement of the Company’s CFO
  • Annual guidance figures will not be updated unless there is a material development
  • Experienced some cost issues in the fourth quarter, including higher employee healthcare expenses
  • Potential impact of the coronavirus

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q4 2019

Historical avgQ4 2019

-0.6%

Avg return

Earnings day

-0.5%

Avg return

5 days after

-1.3%

Avg return

30 days after

53%

35 / 66 earnings

Positive

+17.3%

Q3 2024

Best reaction

-27.5%

Q2 2022

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026+0.5%+1.3%+7.5%
Q4 2025-2.9%+1.9%-8.5%
Q3 2025+0.9%-15.8%-13.8%
Q2 2025+14.7%+20.4%+17.8%
Q1 2025-0.1%+8.8%+8.9%
Q4 2024-6.0%-9.5%-18.0%
Q3 2024+17.3%+14.8%+17.9%
Q2 2024-6.8%-3.9%-5.4%
Q1 2024-2.2%+0.2%-8.0%
Q4 2023+3.4%+2.8%+9.8%
Q3 2023-2.8%-3.3%+4.3%
Q2 2023-8.6%-8.1%-19.8%
Q1 2023+4.5%+10.1%+2.1%
Q4 2022+2.1%+2.2%-5.7%
Q3 2022-8.9%-4.0%-0.3%
Q2 2022-27.5%-29.9%-37.0%
Q1 2022-4.4%-4.1%+4.2%
Q4 2021-5.8%-6.5%-2.1%
Q3 2021-3.6%-8.2%-21.6%
Q2 2021-3.6%-5.4%-1.1%
Q1 2021+6.0%+4.5%+6.6%
Q4 2020-17.2%-19.8%-24.3%
Q3 2020+8.4%+26.6%+29.2%
Q2 2020+2.4%+1.1%+3.7%
Q1 2020-1.0%+2.7%+0.9%
Q4 2019-17.7%-16.0%-49.0%
Q3 2019-20.1%-20.4%-20.5%
Q2 2019+3.9%+6.1%+8.1%
Q1 2019+2.3%+3.3%-1.2%
Q4 2018+3.2%+3.4%+2.1%
Q3 2018+5.1%+6.5%+10.7%
Q2 2018+8.9%+7.0%+18.9%
Q1 2018-1.4%-0.5%+2.4%
Q4 2017+6.8%+2.7%+4.9%
Q3 2017-2.6%-2.9%+5.7%
Q2 2017+2.4%+2.6%-2.9%
Q1 2017-6.0%+0.8%-2.1%
Q4 2016+1.7%+2.0%-1.2%
Q3 2016-1.2%+0.5%+14.3%
Q2 2016+4.7%+4.0%+9.7%
Q1 2016+12.7%
Q4 2015+1.2%
Q3 2015+2.3%
Q2 2015-5.0%
Q1 2015+7.9%
Q4 2014+5.4%
Q3 2014-7.2%
Q2 2014+5.8%
Q1 2014+3.0%
Q4 2013-0.3%
Q3 2013-7.1%
Q2 2013+6.0%
Q1 2013+3.5%
Q4 2012-4.6%
Q3 2012+0.6%
Q2 2012+0.6%
Q1 2011+1.0%
Q1 2012+2.1%
Q4 2009-0.2%
Q4 2011-0.2%
Q3 2011+1.9%
Q3 2010+1.9%
Q2 2010-10.9%
Q2 2011-10.9%
Q4 2010-10.9%
Q1 2010+12.8%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro